International Journal of Medical and Health Research
www.medicalsciencejournal.com
ISSN: 2454-9142
Received: 03-05-2023, Accepted: 18-05-2023, Published: 02-06-2023
Volume 9, Issue 3, 2023, Page No. 14-16

Nectin-4 protein expression and future implications in targeted therapy for colorectal carcinoma

Barani Karikalan[1], Srikumar Chakravarthi[2]
[1] Department of Pathology, Faculty of Medicine, Mahsa University, Saujana Putra, Selangor, Malaysia
[2] Faculty of Medicine, Segi University, Petaling Jaya, Selangor, Malaysia

Abstract
Colorectal carcinoma (CRC) is a significant global health burden, and there is a critical need to identify novel therapeutic targets for improved patient outcomes. Nectin-4, a transmembrane glycoprotein, has emerged as a promising candidate due to its aberrant expression in CRC. This essay aims to provide a comprehensive overview of Nectin-4 protein expression in CRC and its future implications in terms of targeted therapy. The potential benefits and challenges associated with targeting Nectin-4, including diagnostic and prognostic applications, as well as the development of Nectin-4-directed therapies, will be discussed.

Keywords: health, protein, CRC, nectin-4

Introduction
Colorectal carcinoma (CRC) is the third most common cancer worldwide and a leading cause of cancer-related mortality. Despite advancements in treatment strategies, there is a crucial need for the identification of novel therapeutic targets [1, 2]. Nectin-4, a member of the Nectin family of cell adhesion molecules, has emerged as a promising candidate due to its involvement in cell-cell adhesion and signaling processes, as well as its aberrant expression in CRC. Nectin-4 is primarily responsible for cell-cell adhesion and plays a vital role in tissue organization and homeostasis. While its expression is typically restricted to specific epithelial compartments in normal tissues, Nectin-4 is frequently upregulated in various cancers, including CRC. Aberrant Nectin-4 expression has been associated with cancer progression, invasion, metastasis, and poor clinical outcomes. Multiple studies have demonstrated elevated Nectin-4 expression in CRC tissues compared to adjacent normal tissues. Immunohistochemical analyses consistently reveal increased Nectin-4 levels in primary tumors and metastatic lesions. Moreover, Nectin-4 expression has been observed in cancer stem cells within CRC, suggesting its involvement in tumor initiation and therapy resistance [3].
Nectin-4 expression has shown promise as a diagnostic marker for CRC. Immunohistochemical assessment of Nectin-4 expression in biopsy samples may aid in distinguishing malignant tissues from benign conditions, facilitating accurate diagnosis and classification. The identification of Nectin-4 as a cell surface protein opens up the possibility of non-invasive detection using various imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI). Targeting Nectin-4 with radiolabeled probes or contrast agents could provide valuable diagnostic information and aid in disease staging. High Nectin-4 expression levels have been associated with advanced tumor stage, lymph node metastasis, and poor prognosis in patients with CRC. The assessment of Nectin-4 expression could serve as a prognostic indicator, enabling risk stratification and informing personalized treatment decisions [4].

Therapeutic targeting of Nectin-4
Nectin-4 antibodies
Monoclonal antibodies are engineered molecules that specifically recognize and bind to target proteins. They have become a mainstay of cancer treatment, offering improved specificity and reduced off-target toxicity compared to traditional chemotherapy. Nectin-4, a cell adhesion molecule, is overexpressed in colorectal cancer and has emerged as a promising target for mAb-based therapies. mAbs targeting Nectin-4 exert their therapeutic effects through various mechanisms. They can directly bind to Nectin-4 on cancer cells, inhibiting tumor growth and inducing apoptosis [5]. Additionally, mAbs can mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), involving the recruitment of immune cells or the complement system to eliminate cancer cells expressing Nectin-4 [6].
Therapeutic Benefits of mAbs targeting Nectin-4 include its high degree of selectivity, immunomodulatory effects and its potential for achieving synergistic effects when combined with other treatment modalities. mAbs targeting Nectin-4 offer a high degree of selectivity, specifically binding to cancer cells overexpressing this protein. This selectivity minimizes damage to healthy tissues and reduces off-target side effects commonly associated with traditional chemotherapy [7]. In addition to their direct cytotoxic effects, mAbs can modulate the immune response against cancer cells. Nectin-4-targeting mAbs can activate immune cells, such as natural killer (NK) cells and macrophages, through Fc receptor-mediated interactions, enhancing their antitumor activity. Nectin-4-targeting mAbs can be combined with other therapeutic modalities, including chemotherapy, radiation therapy, or immune checkpoint inhibitors, to achieve synergistic effects. Combining mAbs with other treatment approaches may enhance response rates and improve overall patient outcomes [8].
Several Nectin-4-targeting mAbs have entered clinical trials for the treatment of colorectal cancer. These trials aim to evaluate the safety, efficacy, and optimal dosing of Nectin-4 mAbs either as monotherapy or in combination with other agents. Early clinical data have shown promising results,

including objective response rates and prolonged survival in patients with advanced CRC. Despite the potential therapeutic benefits, there are several challenges associated with mAb-based therapies targeting Nectin-4 for colorectal cancer. Tumor cells may develop resistance to mAb therapy through various mechanisms, including downregulation of Nectin-4 expression or alterations in the antibody-binding domain. Understanding these resistance mechanisms is critical for developing strategies to overcome or prevent resistance [9].

Identifying patients who are most likely to respond to Nectin-4-targeting mAbs is essential for optimizing treatment outcomes. Biomarkers or predictive factors that can stratify patients based on Nectin-4 expression or other relevant characteristics may aid in patient selection. Determining the optimal combination partners for Nectin-4-targeting mAbs is an ongoing challenge [10]. Combinatorial approaches require careful consideration of drug interactions, potential overlapping toxicities, and the identification of synergistic treatment regimens. Monoclonal antibodies targeting Nectin-4 offer a promising avenue for the treatment of colorectal cancer. Their selective binding to Nectin-4-expressing cancer cells, immunomodulatory effects, and potential for combination therapies make them attractive candidates for further clinical development. Continued research and clinical trials are needed to establish their safety, efficacy, and long-term outcomes, as well as to address challenges such as resistance mechanisms and patient selection [11].

Antibody-drug conjugates (ADCs)

Antibody-drug conjugates (ADCs) have emerged as a promising approach for targeted cancer therapy, combining the specificity of monoclonal antibodies (mAbs) with the cytotoxicity of chemotherapeutic drugs. This section aims to provide an overview of Nectin-4-targeted ADCs for the treatment of colorectal carcinoma, discussing their mechanism of action, potential benefits, challenges, and current status of development. Antibody-drug conjugates (ADCs) are designed to selectively deliver cytotoxic drugs to cancer cells, while minimizing systemic toxicity [12]. Nectin-4, a cell adhesion molecule, is overexpressed in colorectal carcinoma, making it an attractive target for ADC-based therapies. Nectin-4-targeted ADCs consist of three main components: a monoclonal antibody specific to Nectin-4, a cytotoxic payload, and a linker that connects the antibody and payload [13]. The antibody recognizes and binds to Nectin-4 on cancer cells, leading to internalization of the ADC via receptor-mediated endocytosis. Once inside the cell, the linker is cleaved, releasing the cytotoxic payload, which exerts its antitumor effects [14].

Benefits of Nectin-4-targeted ADCs include its selective targeting capability, enhanced therapeutic index and its potential for achieving synergistic effects when combined with other treatment modalities [15]. Nectin-4-targeted ADCs offer selective delivery of cytotoxic drugs to Nectin-4-expressing cancer cells, minimizing damage to healthy tissues and reducing systemic side effects. ADCs allow for the delivery of highly potent cytotoxic drugs directly to tumor cells, increasing their efficacy while reducing the required systemic dosage and associated toxicity [16]. Nectin-4-targeted ADCs can be combined with other treatment modalities, such as chemotherapy, radiation therapy, or immune checkpoint inhibitors, for synergistic effects, potentially improving treatment outcomes [17].

Challenges and Considerations of Nectin-4-targeted ADCs include achieving optimal linker stability and payload release, heterogeneity of Nectin-4 Expression and overcoming resistance. Achieving optimal linker stability and payload release is critical for ADC efficacy. The linker must be stable in circulation but cleavable in the tumor microenvironment to ensure payload release and subsequent cytotoxic effects. Nectin-4 expression levels may vary within and between patients, presenting challenges for patient selection and predicting response to Nectin-4-targeted ADC therapy [18]. Complementary biomarkers or imaging techniques may be necessary to identify patients who are most likely to benefit from this treatment approach. Similar to other targeted therapies, resistance to Nectin-4-targeted ADCs may develop. Resistance mechanisms, such as alterations in Nectin-4 expression or downstream signaling pathways, need to be elucidated to develop strategies to overcome or prevent resistance [19].

Several Nectin-4-targeted ADCs are currently under investigation in preclinical and clinical studies for the treatment of colorectal carcinoma. These studies aim to evaluate the safety, efficacy, and optimal dosing of Nectin-4 ADCs as monotherapy or in combination with other agents. Early clinical data have shown promising results, including objective response rates and prolonged survival in patients with advanced CRC. Nectin-4-targeted ADCs represent a promising therapeutic approach for the treatment of colorectal carcinoma. Their selective targeting, enhanced therapeutic index, and potential for combination therapies make them attractive candidates for further clinical development. However, challenges such as linker stability, heterogeneity of Nectin-4 expression, and resistance mechanisms need to be addressed. Ongoing research and clinical trials are necessary to fully realize the potential of Nectin-4-targeted ADCs in the management of colorectal carcinoma [20].

Challenges and future directions

Several challenges need to be addressed for the successful translation of Nectin-4-targeted therapies into clinical practice. Standardization of Nectin-4 detection methods, such as immunohistochemistry, is crucial to ensure consistent and reliable results [21]. Additionally, understanding the mechanisms underlying Nectin-4-mediated tumorigenesis and therapy resistance is essential for the development of effective therapeutic strategies [22]. Rigorous preclinical and clinical studies are required to assess the safety, efficacy, and long-term outcomes of Nectin-4-targeted therapies [23]. Combining Nectin-4-targeted therapies with other treatment modalities, such as chemotherapy, radiotherapy, and immune checkpoint inhibitors, holds promise for synergistic effects and improved therapeutic outcomes. Preclinical studies have shown enhanced antitumor activity when Nectin-4 antibodies are combined with conventional treatments [24, 25].

Conclusion

Nectin-4 protein expression in CRC holds great promise as a diagnostic marker, prognostic indicator, and therapeutic target. Targeting Nectin-4 with monoclonal antibodies, ADCs, and combination therapies has the potential to revolutionize the treatment landscape for CRC, improving

patient outcomes and reducing the burden of this devastating disease. Further research and clinical trials are needed to fully exploit the therapeutic potential of Nectin-4 in CRC.

References

1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational oncology, 2021, 14(10). 101174. https://doi.org/10.1016/j.tranon.2021.101174
2. Srikumar Chakravarthi, Barani Karikalan. "Molecular Biomarkers for Lung Adenocarcinoma: A Short Review", Current Cancer Therapy Reviews,2020, 16(1). https://doi.org/10.2174/1573394716666200724164654
3. Barani Karikalan, Srikumar Chakravarthi, Karthikesh Jayakumar, Sudha Arumugam. Nectin-4 In Triple Negative Breast Cancers - A Comprehensive Overview. Bulletin of National Institute of Health Sciences,2022:140(5):2613-2626.
4. Kobecki J, Gajdzis P, Mazur G, Chabowski M. Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review. Diagnostics,2022:12(12):3076. https://doi.org/10.3390/diagnostics12123076
5. Wafa Bouleftour, Aline Guillot, Nicolas Magne. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review. Mol Cancer Ther,2022:21(4):493-501. https://doi.org/10.1158/1535-7163.MCT-21-0846
6. Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel, Switzerland),2020:9(3):34. https://doi.org/10.3390/antib9030034
7. Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert opinion on biological therapy,2021:21(7):863-873. https://doi.org/10.1080/14712598.2021.1929168
8. Habif G, Crinier A, André P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cellular & molecular immunology,2019:16(5),415-422. https://doi.org/10.1038/s41423-019-0224-2
9. Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer research,2021:81(18):4641-4651. https://doi.org/10.1158/0008-5472.CAN-21-1109
10. Fenton SE VanderWeele DJ Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma. Front. Oncol, 2023, 12:1069356. doi: 10.3389/fonc.2022.1069356
11. Gupta K, Jones JC, Farias VA, Mackeyev Y, Singh PK, Quiñones-Hinojosa, A, Krishnan S. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. Frontiers in oncology, 2022, 12, 840241. https://doi.org/10.3389/fonc.2022.840241
12. Marei HE, Cenciarelli C, Hasan A. Potential of antibody–drug conjugates (ADCs) for cancer therapy. Cancer Cell Int,2022:22:255. https://doi.org/10.1186/s12935-022-02679-8
13. Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges.mAbs,2021:13(1):1951427. https://doi.org/10.1080/19420862.2021.1951427
14. Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan, Awais Ullah Ihsan, Juan Zhang; Antibody–Drug Conjugates: A Comprehensive Review. Mol Cancer Res,2020:18(1):3-19. https://doi.org/10.1158/1541-7786.MCR-19-0582
15. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal transduction and targeted therapy,2022:7(1):93. https://doi.org/10.1038/s41392-022-00947-7
16. Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, *et al*. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular cancer therapeutics,2022:21(12):1747-1756. https://doi.org/10.1158/1535-7163.MCT-21-0875
17. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, *et al*. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer research,2016:76(10):3003-3013. https://doi.org/10.1158/0008-5472.CAN-15-1313
18. Wang X, Lu J, Yi C. Research Progress of Nectin-4 as a Targeted Therapy for Ovarian Cancer. Yangtze Medicine,2022:6:114-120.doi:10.4236/ym.2022.64011.
19. Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers,2023:15(6):1845. https://doi.org/10.3390/cancers15061845
20. Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol, 202, 14(20). https://doi.org/10.1186/s13045-021-01035-z
21. Rodler S, Eismann L, Schlenker B, Casuscelli J, Brinkmann I, Sendelhofert A, *et al*. Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value-Need for Biomarker Testi
22. Tanaka Y, Murata M, Shen CH, Furue M, Ito T. NECTIN4: A Novel Therapeutic Target for Melanoma. International journal of molecular sciences, 2021:22(2):976. https://doi.org/10.3390/ijms22020976
23. Bednova O, Leyton JV. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. International journal of molecular sciences,2020:21(19):7268. https://doi.org/10.3390/ijms21197268
24. Varayathu H, Sarathy V, Thomas BE, Mufti SS, Naik R. Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Frontiers in oncology,2021:11:559-161. https://doi.org/10.3389/fonc.2021.559161
25. Hayashi T, Hinata N. Current status and future prospects of antibody–drug conjugates in urological malignancies. Int. J. Urol,2022:29:1100-1108. https://doi.org/10.1111/iju.14925